With a market capitalization (market cap) of $1.37B — a measure of how much the company is worth — MoonLake Immunotherapeutics is the 2367th most valuable company in Healthcare as of August 19, 2026. Shares trade at $16.34, down +0.06% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Visit websiteAs of August 19, 2026, MoonLake Immunotherapeutics (MLTX) is worth $1.37B — this is its market capitalization, the total value of all its outstanding shares.
MoonLake Immunotherapeutics’s market cap is $1.37B, which ranks it #2367 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
MoonLake Immunotherapeutics (MLTX) shares trade at $16.34, down 0.06% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025